In 2025, CRISPR advanced gene editing with safe, effective therapies and AI tools, marking a shift towards real-world applications in medicine and agriculture.

Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan's 44th ...